Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestogen (synthetic progestin) presented as a 52 mg intrauterine system for intrauterine use. It provides long‑acting reversible contraception and is also used to manage heavy menstrual bleeding and endometriosis‑related pain.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirena, a levonorgestrel‑releasing intrauterine system, is indicated for several gynecologic conditions.

- Long‑acting reversible contraception: provides up to five years of highly effective birth control. - Heavy menstrual bleeding: reduces menstrual blood loss and may improve anemia. - Endometriosis‑related pain: alleviates pelvic pain associated with endometriosis.

Levonorgestrel released from Mirena may be associated with a range of adverse reactions.

Common Side Effects: - Irregular bleeding: spotting or changes in menstrual pattern. - Amenorrhea: absence of periods after initial months. - Pelvic pain: mild cramping or discomfort. - Breast tenderness: mild swelling or soreness.

Serious or Rare Side Effects: - Uterine perforation: risk during insertion. - Expulsion: device may be expelled spontaneously. - Infection: pelvic inflammatory disease.

Before insertion, clinicians should consider several safety measures.

- Patient selection: assess uterine size, shape, and absence of active pelvic infection before insertion. - Pregnancy testing: confirm non‑pregnant status prior to placement. - Follow‑up: schedule pelvic exam 4–6 weeks after insertion to verify position. - Contraindications: avoid in women with known or suspected malignancy of the breast or reproductive organs. - Hormonal considerations: monitor for signs of hormonal side effects such as mood changes or weight gain. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from Mirena can interact with other medicines.

Major Interactions (Avoid): - Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may reduce levonorgestrel efficacy. - Rifampicin and other strong CYP3A4 inducers: can lower intrauterine hormone levels. - Antiretroviral protease inhibitors (e.g., ritonavir): may alter hormone metabolism.

Moderate Interactions (Monitor Closely): - Hormonal therapies (e.g., estrogen‑containing contraceptives): may increase hormonal load. - Antifungal azoles (e.g., ketoconazole): potential modest reduction in efficacy. - Herbal supplements (e.g., St. John’s wort): may affect hormone levels.